2004
DOI: 10.1055/s-2004-813059
|View full text |Cite
|
Sign up to set email alerts
|

Conjugated Bile Acid Replacement Therapy in Short Bowel Syndrome Patients with a Residual Colon

Abstract: Cholylsarcosine is efficacious and safe for enhancing fat absorption and nutritional status in short bowel syndrome patients with residual colon. Natural conjugated bile acids improve steatorrhea to a smaller extent and greatly worsen diarrhea.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
14
0
4

Year Published

2007
2007
2023
2023

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 33 publications
(18 citation statements)
references
References 28 publications
(22 reference statements)
0
14
0
4
Order By: Relevance
“…In such patients, administration of desiccated bile improved steatorrhea, but greatly worsened diarrhea. Cholylsarcosine improved fat absorption but, in contrast to desiccated bile, induced little change in fecal weight [98]. Cholylsarcosine no longer has patent protection and may never be brought to market.…”
Section: Bile Acid Replacementmentioning
confidence: 99%
“…In such patients, administration of desiccated bile improved steatorrhea, but greatly worsened diarrhea. Cholylsarcosine improved fat absorption but, in contrast to desiccated bile, induced little change in fecal weight [98]. Cholylsarcosine no longer has patent protection and may never be brought to market.…”
Section: Bile Acid Replacementmentioning
confidence: 99%
“…In patients with ileal resections and steatorrhea but with intact colons, cholylsarcosine increased fat absorption and patients gained weight. 72 However, our use patent was not licensed, and the compound is now in the public domain, precluding its commercial development. The inability to bring cholylsarcosine to the market is one of my failures.…”
Section: Bile Acid Metabolism In Short Bowel Syndromementioning
confidence: 99%
“…Interestingly, it may be feasible to increase UDCA intestinal exposure by the use of a specific type of probiotic (living bacteria) that epimerizes CDCA to UDCA within the intestinal lumen [134] . BAs have been used in some cases as a replacement to reduce steatorrhea due to short bowel syndrome or secondary to metabolic genetic diseases, frequently at the price of enhanced diarrhea [135,136] . Conversely, diarrhea without steatorrhea benefits from treatment with ion exchange www.wjgnet.com resins such as cholestiramine that bind and act as sequestrant of BAs during their intestinal transit [137] .…”
Section: Intestinal Applications Of Bamentioning
confidence: 99%